# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sugar Ray Robinson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX003-SYN
- Date: 2026-07-21
- Fictional facility: St. Posthumous Health Center
- Fictional author: Langston Pryce-Okonjo, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review of memory loss, seen the same day by cognitive neurology. **S**

## History of present illness

Sugar Ray Robinson returns two weeks after intake with his care partner and is seen the same day by Dr. Haddad-Kowalski at the memory clinic. He had a brain MRI and a hearing test this morning. His intake blood count, kidney function, B12 and TSH were normal; hemoglobin A1c was 6.4%. He has slept well since stopping the over-the-counter sleep aid. He has not driven since intake; his care partner drives. The handgun stays unloaded and locked with the key held by his care partner. He repeated one question twice during the visit and laughed about it. **S**

| Element | Detail |
|---|---|
| MMSE | 22 |
| CDR | Global 1, sum of boxes 5.5 |
| MRI | Hippocampal atrophy; six microbleeds; no superficial siderosis; cavum septi pellucidi |
| Audiometry | Mild to moderate bilateral high-frequency hearing loss |
| Sleep | Sleeping well without diphenhydramine |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Neurological | Positive | Memory loss; no headaches, weakness, tremor, falls or change in walking |
| Psychiatric | Negative | No low mood, hallucinations, suspiciousness or irritability |
| Ears, nose, mouth, and throat | Positive | Asks people to repeat themselves in noisy rooms |
| Endocrine | Negative | No low glucose spells he or his care partner has noticed |

4 systems reviewed. **S**

## Current medications

- Metformin 1,000 mg oral tablet, one tablet twice daily with meals **S**
- Glipizide 5 mg oral tablet, one tablet before breakfast **S**
- Lisinopril 20 mg oral tablet, one tablet daily **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/78 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 76.8 kg; BMI 23.7 kg/m². All vital signs are synthetic.

MMSE: 22; CDR (global): 1. All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Well and cheerful; blood pressure 128/78; pulse 70; weight 76.8 kg |
| Neurological | Cranial nerves normal; no rigidity, tremor or slowness; normal strength and reflexes; steady narrow-based gait; no dysarthria |
| Mental status | Alert and courteous; repeats questions; mood good; no psychotic symptoms |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Memory loss with getting lost** (R41.3). Dr. Haddad-Kowalski finds mild dementia (CDR 1, MMSE 22) with an amnestic pattern and hippocampal atrophy, most likely due to Alzheimer's disease; long exposure to repetitive head impacts raises traumatic encephalopathy syndrome, a research diagnosis, as a contributor; vascular change is slight. Reversible causes have been excluded or treated. The six microbleeds rule out lecanemab and donanemab under the appropriate use recommendations, so APOE genotyping is not needed for that decision. An amyloid PET will confirm or exclude Alzheimer's disease, which he wants to know. **S**
   - Amyloid PET in two weeks.
   - Results and next steps at the six-week visit, with his care partner present at his request.
   - No driving until then.
2. **Bilateral sensorineural hearing loss** (H90.3). Mild to moderate high-frequency loss that makes conversation harder and may add to his difficulty; hearing aids can help. **S**
   - Hearing aid assessment with the audiologist.
3. **Type 2 diabetes** (E11.9). Hemoglobin A1c 6.4% on metformin and glipizide, below his goal; the sulfonylurea will be reviewed when the diagnosis is settled. **S**
   - Home glucose readings twice a day until the next visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Cognitive testing (MoCA, MMSE) | At diagnosis, then yearly, or sooner with change | Completed today | MoCA 18 at intake; MMSE 22 today |
| Survey | Dementia staging (CDR) and function (ADL and IADL) | At diagnosis, then yearly | Completed today | Global CDR 1 (sum of boxes 5.5); independent in personal care, needs help with bills, medicines and appointments (Functional Activities Questionnaire 11) |
| Laboratory | Reversible causes: blood count, metabolic panel, B12, TSH, depression, sleep apnea, hearing | Once at diagnosis | Completed today | Blood count, metabolic panel, B12 352 pg/mL and TSH 1.9 at intake, normal; PHQ-9 4; diphenhydramine stopped; STOP-Bang 2 (low risk of sleep apnea); hearing loss on audiometry today |
| Imaging | Brain MRI | Once at diagnosis; repeat only with an acute change | Completed today | Moderate hippocampal atrophy; six microbleeds; no siderosis or infarct; cavum septi pellucidi |
| Imaging | Amyloid biomarker confirmation (PET or CSF) | Once, when it will change diagnosis or treatment | Ordered | Amyloid PET booked in two weeks |
| Medication safety | Anti-amyloid antibody eligibility (lecanemab, donanemab), APOE genotyping and ARIA MRI schedule | At diagnosis of MCI or mild dementia due to Alzheimer's disease | Not indicated | Not a candidate: more than four cerebral microbleeds exclude lecanemab and donanemab under both appropriate use recommendations; APOE genotyping therefore not needed for treatment and offered only with counseling (declined); no ARIA monitoring schedule |
| Medication safety | Medicine review for anticholinergic and sedating drugs (Beers) | Every visit | Completed today | Diphenhydramine stopped at intake; no other anticholinergic or sedating drugs |
| Survey | Behavioral and psychological symptoms (NPI-Q items) | Every visit | Completed today | None: no agitation, apathy, low mood, anxiety, hallucinations, delusions or sleep disturbance |
| Medication safety | Cholinesterase inhibitor: benefit, nausea, diarrhea, dreams, pulse | Each follow-up and each dose change | Not indicated | Not started until the cause is confirmed |
| Self-management | Driving, firearm and home safety | At diagnosis and each follow-up | Completed today | Not driving; handgun unloaded and locked with the key held by his care partner; no wandering |
| Self-management | Care partner support and burden (Zarit, narrative) | At diagnosis, then at least yearly | Due | At the diagnosis visit |
| Self-management | Advance care planning | At diagnosis; revisit yearly and at changes | Due | Planned at the preventive visit |
| Laboratory | Hemoglobin A1c, goal under 8.0% for an older adult with cognitive impairment, and hypoglycemia review | Every three months after a therapy change; every six months when stable | Up to date | 6.4% at intake; no low readings |
| Examination | Blood pressure, goal under 130/80 mmHg | Every visit | Completed today | 128/78 mmHg on lisinopril |
| Laboratory | Potassium and creatinine on lisinopril and metformin | Yearly, and after acute illness or dehydration | Up to date | Potassium 4.4 mmol/L, creatinine 1.0 mg/dL at intake |
| Examination | Dilated diabetic eye examination | Every one to two years without retinopathy | Referred | Requested at intake; appointment pending |
| Referral | Cognitive neurology consultation | At diagnosis | Completed today | Seen by Dr. Haddad-Kowalski today |

## Goal progress

- Find the cause of the memory loss and explain it to him in a way he can take in. In progress; target 2026-08-18. **S**
- No hypoglycemia, with hemoglobin A1c under 8.0%. In progress; target 2026-10-27. **S**
- Stay safe: no driving and no firearm in the home. In progress; target 2026-08-18. **S**
- Keep his days full and give his care partner regular breaks. In progress; target 2026-10-27. **S**

## Guideline basis

- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024), Alzheimer's Association (Alzheimers Dement 2025;21(1):e14337)
- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care (2024), Alzheimer's Association (Alzheimers Dement 2025)
- CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, diabetes type 2 and hypertension monographs (2026), Aether Forge
- Lecanemab: Appropriate Use Recommendations (2023), J Prev Alzheimers Dis 2023;10(3):362-377 (Cummings J et al.)
- Donanemab: Appropriate use recommendations (2025), J Prev Alzheimers Dis 2025;12(5):100150 (Rabinovici GD et al.)
- National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021), Neurology 2021;96(18):848-863
- American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023), American Geriatrics Society (Journal of the American Geriatrics Society)
- Practice Parameter update: Evaluation and management of driving risk in dementia (2010), American Academy of Neurology (Neurology 2010;74(16):1316-1324)

## Follow-up

- Amyloid PET in two weeks. Six-week review for results, with his care partner. Hearing aid assessment. Call with any new confusion, falls or low glucose readings. **S**
- Next scheduled visit 2026-08-18: six-week review: amyloid PET result, the diagnosis and the plan, with diabetes, driving, firearm and caregiver support. **S**
